Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.65 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.39 |
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 2/20 | 0.65 |
| ▸ | SI | P14410 | 2/20 | 0.65 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL53913 | 0.96 | — | — | |
| SCHEMBL3441102 | 0.96 | MGAM (0.69) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL708003 | 0.92 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL29911291 | 0.92 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| Bromide SCHEMBL29190335 | 0.92 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| Lithium SCHEMBL11306430 | 0.92 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL11587161 | 0.92 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL9461843 | 0.92 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL4776595 | 0.92 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL27939824 | 0.92 | MGAM (0.65) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554569-A1 | AGENT CONTAINING MALONIC ACID OR ITS DERIVATIVES FOR RESTORING METAL HOMEOSTASIS | Oxford Antibiotic Group GmbH (AT) | 2025-05-21 | — | — | EP | disclosed |
| CN-119866217-A | Agent for restoring metal steady state containing malonic acid or derivative thereof | 牛津抗生素(制药)集团股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-113677657-B | Polymerizable liquid crystal composition, liquid crystal display element, and compound | 石家庄诚志永华显示材料有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119630673-A | PDE4B inhibitors and uses thereof | 西藏海思科制药有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-116600808-B | Tetrahydronaphthyridine derivative serving as KRAS mutant G12C inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024067708-A1 | AMMONIUM OXALATE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PHARMACEUTICAL USE OF SAME | 苏州阿尔脉生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024067709-A1 | PYRIDINYLAMIDE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND MEDICAL USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024067566-A1 | SATURATED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PHARMACEUTICAL USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024032673-A1 | PDE4B INHIBITOR AND USE THEREOF | 西藏海思科制药有限公司 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024013400-A1 | AGENT CONTAINING MALONIC ACID OR ITS DERIVATIVES FOR RESTORING METAL HOMEOSTASIS | OXFORD ANTIBIOTIC GROUP GMBH (AT) | 2024-01-18 | — | — | WO | disclosed |
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-06-05 | — | — | US | disclosed |
| CN-101151267-A | Chemical compounds | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | CN | disclosed |
| US-7326791-B2 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-02-05 | — | — | US | disclosed |
| US-20040220169-A1 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-11-04 | — | — | US | disclosed |
| CN-1113881-C | 8-substituted-1,3,8-triaza-spiro [4,5] decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2003-07-09 | — | — | CN | disclosed |
| US-6248770-B1 | CARDIOVASCULAR DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-06-19 | — | — | US | disclosed |
| CN-1191862-A | 8-substituted-1,3,8-triaza-spiro [4,5] decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 1998-09-02 | — | — | CN | disclosed |
| US-5466708-A | Carbamyloxyoxetanone compounds | HOFFMANN-LA ROCHE INC. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5376674-A | Lipase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5260310-A | Oxetanone compounds and pharmaceutical compositions containing them | HOFFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | GAA 370/4885HSP90AB1 4236/4885POLA1 664/4885 |
| US-20040220169-A1 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | F12, F11, F2 | GAA 304/4885HSP90AB1 3734/4885POLA1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.